| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11:46 | Jazz and AbCellera sign deal for T-cell engagers in solid tumours | ||
| 11:46 | LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs | ||
| Mi | Biopharma bounces back as M&A impetus fuels recovery | ||
| Mi | Vedana debuts with $46m to progress migraine therapies | ||
| Mi | AviadoBio broadens vMiX gene silencing licence with King's College London | ||
| Mi | Altaris to acquire Simulations Plus in $375m all-cash deal | ||
| Mi | Zai Lab's zocilurtatug pelitecan secures EMA orphan drug status | ||
| Di | HLTH Europe 2026: obesity drugs shift the paradigm, but systemic implementation lags | ||
| Di | Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug | ||
| Di | FDA and MHRA forge new regulatory collaboration initiative | ||
| Di | Alkermes' alixorexton secures FDA and EC orphan designations | ||
| Di | ALK's EURneffy secures MHRA approval for anaphylaxis treatment | ||
| Mo | Younger UK children to benefit from new dose of nasal spray allergy drug | ||
| Mo | FDA oncology roundup: drugs, imaging agents and diagnostics gain approval | ||
| Mo | Simcere and Stanford partner to develop IPF therapies | ||
| Mo | FDA clears MSD's Keytruda combo plus Welireg for ccRCC treatment | ||
| Fr | Novo Nordisk comeback stirs as Wegovy pill wins UK approval | ||
| Fr | China's NMPA approves Akeso's gumokimab for plaque psoriasis | ||
| Fr | FDA grants priority review for Roche's Tecentriq combo sBLA | ||
| 11.06. | Drug developers eye sport's biggest stage as World Cup fever builds | ||
| 11.06. | XtalPi enters $400m partnership for small molecule therapy for GPCR target | ||
| 11.06. | Beren pockets $300m to take Niemann-Pick disease therapy to market | ||
| 11.06. | EMA validates Bayer's asundexian application for ischaemic stroke | ||
| 10.06. | Parabilis Medicines sets biotech record with $670m IPO | ||
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement |